Tumor News and Research

RSS

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine.

5 Jan 2010

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease.

5 Jan 2010

A 'cocktail' to kill cancerous tumors

A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancerous tumors.

5 Jan 2010

Scientists uncover an important link between inflammation and breast cancer stem cells

Scientists at the University of Michigan Comprehensive Cancer Center have uncovered an important link between inflammation and breast cancer stem cells that suggests a new way to target cells that are resistant to current treatments.

4 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

Novelos continues NOV-002 Phase 3 combination trial for lung cancer

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer candidate figitumumab (CP-751,871) while Novelos' pivotal Phase 3 trial, with a primary efficacy endpoint of improvement in median overall survival, continues across approximately 12 countries and 100 clinical sites.

4 Jan 2010

Scientists identify genetic marker to diagnose DFTD

An international team of scientists led by a Cold Spring Harbor Laboratory (CSHL) investigator has discovered that the deadly facial tumors decimating Australia's Tasmanian devil population probably originated in Schwann cells, a type of tissue that cushions and protects nerve fibers.

4 Jan 2010

Children's Hospital of Philadelphia SDU delivers babies prenatally diagnosed with complex birth defects

More than 240 babies born in 2009 in the Garbose Family Special Delivery Unit (SDU) at The Children's Hospital of Philadelphia are ringing in 2010 with their joyful families. Families from 24 states traveled to Children's Hospital for expert prenatal, delivery and postnatal care for their babies.

30 Dec 2009

TheScientist honors Seahorse Bioscience's XF96 Extracellular Flux Analyzer as a 2009 Top Ten Innovation

Seahorse Bioscience, Inc., leader in the design and development of instruments for measuring cellular bioenergetics, announced that TheScientist magazine cited their XF96 Extracellular Flux Analyzer as a 2009 Top Ten Innovation.

30 Dec 2009

Results from Bionovo's study on BN107 published

Bionovo, Inc. announced today the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative (ER-) breast cancer cells.

29 Dec 2009

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.

29 Dec 2009

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

29 Dec 2009

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Self-seeding process of cancer cells can enhance tumor growth, says study

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs.

27 Dec 2009

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

24 Dec 2009

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

Discovery enables scientists to devise novel strategies to diagnose and treat brain cancer

A team of Columbia scientists have discovered two genes that, when simultaneously activated, are responsible for the most aggressive forms of human brain cancer.

23 Dec 2009

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.

23 Dec 2009

Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo

Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.

23 Dec 2009

Tumor News and Research

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

A 'cocktail' to kill cancerous tumors

Scientists uncover an important link between inflammation and breast cancer stem cells

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Novelos continues NOV-002 Phase 3 combination trial for lung cancer

Scientists identify genetic marker to diagnose DFTD

Children's Hospital of Philadelphia SDU delivers babies prenatally diagnosed with complex birth defects

TheScientist honors Seahorse Bioscience's XF96 Extracellular Flux Analyzer as a 2009 Top Ten Innovation

Results from Bionovo's study on BN107 published

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Self-seeding process of cancer cells can enhance tumor growth, says study

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Study suggests routine evaluation does not predict prostate cancer

New compound may halt drug-resistant lung cancer

Discovery enables scientists to devise novel strategies to diagnose and treat brain cancer

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News